Clinical trials: Central Nervous System Neoplasms, Primary
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Primary Brain Tumor, Glioma
Assistance in Neurosurgery (ExtempoRMN)
The main ambition of this project is to develop, and provide the medical community, an innovative method to analyze extemporaneously, during a neurosurgery operation, excised tissues.
- Trial name
- ExtempoRMN (NCT02272452)
- Testing
- High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Lymphoma
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity
- Trial name
- NCT00734773
- Testing
- Rituximab, Cytarabine, Methotrexate
- Sponsor
- Northwestern University
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide…
- Trial name
- NCT00000801
- Testing
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ataxia-Telangiectasia
Study for Treatment of Cancer in Children With Ataxia-telangiectasia
This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.
- Trial name
- NCT00187057
- Testing
- vinblastine, vincristine, prednisone, daunorubicin, doxorubicin, methotrexate, cyclophosphamide, L-asparaginase, etoposide, cytarabine, mercaptopurine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Jude Children's Research Hospital
Primary Brain Tumour, Radiation Toxicity
Cognitive Function After Radiation Therapy for Primary Brain Tumours
This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction.
- Conditions
- Primary Brain Tumour, Radiation Toxicity, Cognitive Impairment
- Trial name
- NCT04306432
- Testing
- Cognitive tests and Patient Reported Outcomes
- Where
- 5 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Tuberous Sclerosis Complex
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
The purpose of the study is to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with Tuberous Sclerosis Complex (TSC).
- Trial name
- ViRap (NCT04987463)
- Testing
- Vigabatrin, Rapamycin
- Where
- 2 sites in Poland
- Volunteers
- 60 people
- Sponsor
- Katarzyna Kotulska
Lymphoma
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
The purpose of this study is to evaluate two types of chemotherapy for primary central nervous system lymphoma in the elderly (age older than 60) : Methotrexate, procarbazine, vincristine and cytarabine Methotrexate and…
- Trial name
- CNSLymphoma (NCT00503594)
- Testing
- Methotrexate and temozolomide, Methotrexate , procarbazine ,vincristine ,cytarabine
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Central Nervous System Cancer
Short Course Radiotherapy
This is a single arm prospective pilot trial determining the safety of short-course radiation therapy in pediatric patients with incurable central nervous system malignancies.
- Trial name
- NCT07147179
- Testing
- Short Course Radiotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083096
- Testing
- lonafarnib, temozolomide
- Where
- 3 sites in France, Switzerland
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Refractory Cancer, CNS Tumors
A Study of Avutometinib for People With Solid Tumor Cancers
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults.
- Conditions
- Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- NCT06104488
- Testing
- Avutometinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Brain (Nervous System) Cancers
A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）
Recurrent or progressive primary malignant brain tumors are among the malignancies with a poor prognosis. They refer to primary brain tumors that either recur after standard treatment or show disease progression during the course…
- Trial name
- NCT07496073
- Testing
- CHT 101
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital